Gan to kagaku ryoho. Cancer & chemotherapy 2013-11-01

[A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy].

Koichi Deguchi, Kazuhiro Nishikawa, Kazuhiro Iwase, Junji Kawada, Toyokazu Aono, Hiroshi Yoshida, Masaya Nomura, Hiroshi Tamagawa, Chu Matsuda, Takashi Deguchi, Shigeyoshi Higashi, Yuichiro Okumura, Yuki Noguchi, Masatoshi Nomura, Mari Takagi, Akiko Fukui, Yasuhiro Tanaka

Index: Gan To Kagaku Ryoho. 40(12) , 2253-5, (2013)

Full Text: HTML

Abstract

We report a case of human epidermal growth factor receptor(HER)2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin(CDDP), and trastuzumab as first-line chemotherapy. A 66-year-old woman diagnosed as having advanced gastric cancer underwent chemotherapy after abdominal computed tomography (CT)revealed multiple metastases to the liver, lung, lymph nodes, and peritoneum. Histopathological examination indicated a type 3, tub1, cT3(SS), N3, H1, P1, M1(LYM, PUL), cStage IV gastric tumor. Because overexpression of HER2 protein was observed in primary tumor immunostaining, combination therapy of capecitabine+CDDP+trastuzumab was administered as first-line chemotherapy. After 4 courses, CT scans revealed decreased primary tumor size, liver lesion, lymph nodes, and elimination of the lung lesion, thereby suggesting a partial response(PR). The grade 3 adverse events were neutropenia, anemia, and anorexia. After discontinuation of CDDP because of elevation of serum creatinine levels, combination therapy with capecitabine and trastuzumab was continued.